Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.

Samuel Cytryn,Salman Rafi Punekar,Megan Tenet,Tasfiq Ullah,Bin Wang,Judith D. Goldberg,Vamsidhar Velcheti,Kwok-Kin Wong,Abraham Chachoua,Elaine Shum,Joshua K. Sabari

Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.

2020

Samuel Cytryn
Salman Rafi Punekar
Megan Tenet
Tasfiq Ullah
Bin Wang
Judith D. Goldberg
Vamsidhar Velcheti
Kwok-Kin Wong
Abraham Chachoua
Elaine Shum
Joshua K. Sabari

e21679Background: Third generation EGFR tyrosine kinase inhibitor (TKI) osimertinib demonstrated superior PFS and OS compared to earlier generation TKIs in pts with EGFR+ NSCLC. These pts are dispr...

Keywords:

Oncology
Osimertinib
Progression-free survival
Internal medicine
Pathology
non-small cell lung cancer (NSCLC)
Mutant
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations